<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384384</url>
  </required_header>
  <id_info>
    <org_study_id>S51/05</org_study_id>
    <nct_id>NCT00384384</nct_id>
  </id_info>
  <brief_title>Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients</brief_title>
  <official_title>Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <brief_summary>
    <textblock>
      Background: 18B Glycyrrhetinic acid (active compound of Licorice) decreases serum potassium
      via enhanced renal potassium loss in healthy individuals and thereby inducing renal sodium
      retention and arterial hypertension.In dialysis patients this mechanism is disturbed and
      compensatory intestinal potassium secretion is enhanced. 18B Glycyrrhetinic acid is an
      inhibitor of 11B Hydroxysteroid dehydrogenase type 1 (11b HSD1). Inhibition of 11 b HSD1
      offers a novel potential therapy to lower intracellular cortisol concentrations and thereby
      enhance insulin sensitivity.

      Hypothesis: Glycyrrhetinic acid decreases serum potassium by enhanced intestinal excretion in
      dialysis patients and increases insulin sensivity by inhibition of 11b HSD

      Methods: double blind, 6 month cross over trial comparing oral 18b Glycyrrhetinic acid with
      placebo in 24 nondiabetic dialysis patients.

      Endpoints: predialytic serum potassium levels, insuline sensitivity assessed by fasting
      glucose and fasting insulin concentrations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>End Stage Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral 18B Glycyrrhetinic acid versus placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dialysis patients (&gt;3 months)

        Exclusion Criteria:

          -  diabetics

          -  hospital stay in the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix J Frey, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology and Hypertension, University hospital of Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of nephrology and hypertension, University hospital of berne</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>January 12, 2011</last_update_submitted>
  <last_update_submitted_qc>January 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2011</last_update_posted>
  <keyword>Dialysis</keyword>
  <keyword>Serum potassium</keyword>
  <keyword>18b glycyrrhetinic acid</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glycyrrhetinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

